Expanding the phenotype of hereditary renal cell carcinoma syndromes: Implications for surveillance and management

Clicks: 3
ID: 326309
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #184 of 333 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 333 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Approximately 5% of renal cell carcinoma (RCC) occurs in the setting of a hereditary RCC syndrome, but accurate phenotype and cancer risk estimates remain limited by ascertainment bias in reported series. METHODS: We analyzed 32,728 cancer patients who underwent paired tumor-normal sequencing with MSK-IMPACT for germline pathogenic variants (PVs) in RCC hereditary syndrome genes VHL, FLCN, BAP1, MET, SDHB, FH, and proposed RCC risk variants MITF E318K and FH K477dup. We integrated clinical, tumor immunohistochemistry, and genomic data. We performed burden testing across tumor types and, using case-control analysis, validated novel gene-cancer associations with UK Biobank data. RESULTS: Germline PVs diagnostic of hereditary RCC syndromes were identified in 109 of 32,728 patients (0.33%), including 3.6% of RCC cases. Only 61.5% of carriers met clinical criteria for their syndromes and most patients were undiagnosed prior to testing. Using burden testing, we confirm and suggest novel cancer associations, including BAP1 PVs in hepatobiliary cancers and FLCN in colorectal cancer. We independently validated in the UK Biobank the association of FLCN and colorectal cancer, but analysis of BAP1 and hepatobiliary was limited by small numbers. Tumor analyses demonstrated biallelic inactivation in syndromic tumors and supported pathogenic roles for BAP1 in hepatobiliary cancers and FLCN in colorectal cancers. The FH K477dup pathogenic variant appears to lack association with RCC risk and there was weak evidence for association of MITF E318K. CONCLUSIONS: Using large, unselected pan-cancer cohorts and integrated tumor and genomic analysis can help refine the phenotype of rare cancer predisposition syndromes.
Reference Key
openalex_W7204083462 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Maria I. Carlo, Andrew Schroeder, Jie Liu, Vignesh Ravichandran, Nikita Mehta, Yelena Kemel, Grace Zong, Ying Liu, Alicia Latham, Neil Shah, Darren Feldman, Martin H Voss, Ritesh Kotecha, Zsofia K Stadler, Mark E. Robson, Miika Mehine, Chaitanya Bandlamudi, Michael F Berger, YingBei Chen, Diana Mandelker, Kelly Bolton, Semanti Mukherjee, Kenneth Offit, Robert Motzer
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag290
URL
https://doi.org/10.1093/jnci/djag290
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.